PNPLA2 and Hepatic fibrosis: and (d) Is hepatic ATGL of clinical relevance and should it be targeted as a potential therapeutic strategy for liver diseases, including fatty liver disease, steatohepatitis, hepatic fibrosis, or even liver cancer?